Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses

Cell Host and Microbe

Volumn 18, Issue 3, 2015, Pages 354-362

  Moody, M Anthony ^a   Gao, Feng ^a   Gurley, Thaddeus C ^a   Amos, Joshua D ^a   Kumar, Amit ^a   Hora, Bhavna ^a   Marshall, Dawn J ^a   Whitesides, John F ^a   Xia, Shi Mao ^a   Parks, Robert ^a   Lloyd, Krissey E ^a   Hwang, Kwan Ki ^a   Lu, Xiaozhi ^a   Bonsignori, Mattia ^a   Finzi, Andrés ^b,n   Vandergrift, Nathan A ^a   Alam, S Munir ^a   Ferrari, Guido ^a   Shen, Xiaoying ^a   Tomaras, Georgia D ^a   Kamanga, Gift ^c   Cohen, Myron S ^d   Sam, Noel E ^e   Kapiga, Saidi ^f   Gray, Elin S ^g,o   Tumba, Nancy L ^g   Morris, Lynn ^a,g   Zolla Pazner, Susan ^h,i,p   Gorny, Miroslaw K ^h   Mascola, John R ^j   Hahn, Beatrice H ^k   Shaw, George M ^k   Sodroski, Joseph G ^l   Liao, Hua Xin ^a   Montefiori, David C ^a   Hraber, Peter T ^m   Korber, Bette T ^m   Haynes, Barton F ^a   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l HARVARD MEDICAL SCHOOL   (United States)

^m LOS ALAMOS NATIONAL LABORATORY   (United States)

ⁿ MCGILL UNIVERSITY   (Canada)

^o EDITH COWAN UNIVERSITY   (Australia)

^p MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN G1; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; V3 LOOP PEPTIDE; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA;

ARTICLE; B LYMPHOCYTE; BINDING SITE; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN BINDING; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION; CD4+ T LYMPHOCYTE; DNA SEQUENCE; GENETIC SELECTION; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; MUTATION; VIROLOGY; VIRUS ATTACHMENT;

ANTIBODIES, NEUTRALIZING; BINDING SITES; CD4-POSITIVE T-LYMPHOCYTES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; MOLECULAR SEQUENCE DATA; MUTATION; RNA, VIRAL; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; VIRUS ATTACHMENT;

EID: 84941285955     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2015.08.006     Document Type: Article

References (33)

1. S.S. Balla-Jhagjhoorsingh, D. Corti, L. Heyndrickx, E. Willems, K. Vereecken, D. Davis, and G. Vanham The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody PLoS ONE 8 2013 e68863
2. M. Bouvin-Pley, M. Morgand, L. Meyer, C. Goujard, A. Moreau, H. Mouquet, M. Nussenzweig, C. Pace, D. Ho, P.J. Bjorkman, and et al. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies J. Virol. 88 2014 13910 13917
3. C.A. Derdeyn, P.L. Moore, and L. Morris Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection Curr. Opin. HIV AIDS 9 2014 210 216
4. F. Gao, M. Bonsignori, H.X. Liao, A. Kumar, S.M. Xia, X. Lu, F. Cai, K.K. Hwang, H. Song, T. Zhou, and et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies Cell 158 2014 481 491
5. P.B. Gilbert, M.L. Peterson, D. Follmann, M.G. Hudgens, D.P. Francis, M. Gurwith, W.L. Heyward, D.V. Jobes, V. Popovic, S.G. Self, and et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial J. Infect. Dis. 191 2005 666 677
6. M.K. Gorny, X.-H. Wang, C. Williams, B. Volsky, K. Revesz, B. Witover, S. Burda, M. Urbanski, P. Nyambi, C. Krachmarov, and et al. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1 Mol. Immunol. 46 2009 917 926
7. R. Gottardo, R.T. Bailer, B.T. Korber, S. Gnanakaran, J. Phillips, X. Shen, G.D. Tomaras, E. Turk, G. Imholte, L. Eckler, and et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial PLoS ONE 8 2013 e75665
8. E.S. Gray, M.C. Madiga, T. Hermanus, P.L. Moore, C.K. Wibmer, N.L. Tumba, L. Werner, K. Mlisana, S. Sibeko, C. Williamson, et al. CAPRISA002 Study Team The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection J. Virol. 85 2011 4828 4840
9. H. Haim, B. Strack, A. Kassa, N. Madani, L. Wang, J.R. Courter, A. Princiotto, K. McGee, B. Pacheco, M.S. Seaman, and et al. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity PLoS Pathog. 7 2011 e1002101
10. H. Haim, I. Salas, K. McGee, N. Eichelberger, E. Winter, B. Pacheco, and J. Sodroski Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency Cell Host Microbe 14 2013 547 558
11. B. Haldar, S. Burda, C. Williams, L. Heyndrickx, G. Vanham, M.K. Gorny, and P. Nyambi Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies PLoS ONE 6 2011 e17253
12. B.F. Haynes, P.B. Gilbert, M.J. McElrath, S. Zolla-Pazner, G.D. Tomaras, S.M. Alam, D.T. Evans, D.C. Montefiori, C. Karnasuta, R. Sutthent, and et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial N. Engl. J. Med. 366 2012 1275 1286
13. C.E. Hioe, T. Wrin, M.S. Seaman, X. Yu, B. Wood, S. Self, C. Williams, M.K. Gorny, and S. Zolla-Pazner Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes PLoS ONE 5 2010 e10254
14. P. Hraber, M.S. Seaman, R.T. Bailer, J.R. Mascola, D.C. Montefiori, and B.T. Korber Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection AIDS 28 2014 163 169
15. H.R. Kelly, M. Urbanski, S. Burda, P. Zhong, F. Konings, J. Nanfack, M. Tongo, T. Kinge, J. Achkar, and P. Nyambi Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals Hum. Antibodies 14 2005 89 99
16. F. Klein, L. Nogueira, Y. Nishimura, G. Phad, A.P. West Jr., A. Halper-Stromberg, J.A. Horwitz, A. Gazumyan, C. Liu, T.R. Eisenreich, and et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants J. Exp. Med. 211 2014 2361 2372
17. H.-X. Liao, R. Lynch, T. Zhou, F. Gao, S.M. Alam, S.D. Boyd, A.Z. Fire, K.M. Roskin, C.A. Schramm, Z. Zhang, et al. NISC Comparative Sequencing Program Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus Nature 496 2013 469 476
18. A. Malek, R. Sager, P. Kuhn, K.H. Nicolaides, and H. Schneider Evolution of maternofetal transport of immunoglobulins during human pregnancy Am. J. Reprod. Immunol. 36 1996 248 255
19. J.R. Mascola, and B.F. Haynes HIV-1 neutralizing antibodies: understanding nature's pathways Immunol. Rev. 254 2013 225 244
20. D.C. Montefiori, C. Karnasuta, Y. Huang, H. Ahmed, P. Gilbert, M.S. de Souza, R. McLinden, S. Tovanabutra, A. Laurence-Chenine, E. Sanders-Buell, and et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials J. Infect. Dis. 206 2012 431 441
21. J.P. Moore, Q.J. Sattentau, R. Wyatt, and J. Sodroski Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies J. Virol. 68 1994 469 484
22. J.B. Munro, J. Gorman, X. Ma, Z. Zhou, J. Arthos, D.R. Burton, W.C. Koff, J.R. Courter, A.B. Smith 3rd, P.D. Kwong, and et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions Science 346 2014 759 763
23. P. Nyambi, S. Burda, M. Urbanski, L. Heyndrickx, W. Janssens, G. Vanham, and A. Nadas Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals AIDS Res. Hum. Retroviruses 24 2008 1507 1519
24. S.R. Permar, Y. Fong, N. Vandergrift, G.G. Fouda, P. Gilbert, R. Parks, F.H. Jaeger, J. Pollara, A. Martelli, B.E. Liebl, and et al. Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission J. Clin. Invest. 125 2015 2702 2706
25. D.D. Richman, T. Wrin, S.J. Little, and C.J. Petropoulos Rapid evolution of the neutralizing antibody response to HIV type 1 infection Proc. Natl. Acad. Sci. USA 100 2003 4144 4149
26. J.F. Salazar-Gonzalez, M.G. Salazar, B.F. Keele, G.H. Learn, E.E. Giorgi, H. Li, J.M. Decker, S. Wang, J. Baalwa, M.H. Kraus, and et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection J. Exp. Med. 206 2009 1273 1289
27. J.F. Scheid, H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y.K. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, and et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding Science 333 2011 1633 1637
28. M.S. Seaman, H. Janes, N. Hawkins, L.E. Grandpre, C. Devoy, A. Giri, R.T. Coffey, L. Harris, B. Wood, M.G. Daniels, and et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies J. Virol. 84 2010 1439 1452
29. G.D. Tomaras, J.M. Binley, E.S. Gray, E.T. Crooks, K. Osawa, P.L. Moore, N. Tumba, T. Tong, X. Shen, N.L. Yates, and et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals J. Virol. 85 2011 11502 11519
30. C. Upadhyay, L.M. Mayr, J. Zhang, R. Kumar, M.K. Gorny, A. Nádas, S. Zolla-Pazner, and C.E. Hioe Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope J. Virol. 88 2014 12853 12865
31. X. Wei, J.M. Decker, S. Wang, H. Hui, J.C. Kappes, X. Wu, J.F. Salazar-Gonzalez, M.G. Salazar, J.M. Kilby, M.S. Saag, and et al. Antibody neutralization and escape by HIV-1 Nature 422 2003 307 312
32. X. Wu, T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N.S. Longo, M. Louder, K. McKee, et al. NISC Comparative Sequencing Program Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing Science 333 2011 1593 1602
33. S. Zolla-Pazner, A. deCamp, P.B. Gilbert, C. Williams, N.L. Yates, W.T. Williams, R. Howington, Y. Fong, D.E. Morris, K.A. Soderberg, and et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection PLoS ONE 9 2014 e87572